---
schema_version: "secwatch.filing_event.v1"
accession: "0000950103-22-011927"
form_type: "8-K"
ticker: "PGEN"
cik: "0001356090"
company_name: "PRECIGEN, INC."
filed_at: "2022-07-05T23:59:59+00:00"
generated_at: "2026-06-24T21:13:55.726472+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Precigen agrees to sell Trans Ova Genetics to URUS for $170M upfront cash plus $10M earn-out

## Summary
- Total consideration up to $180M: $170M cash at closing plus $10M earn-out based on 2022-2023 performance.
- Transaction expected to close in Q3 2022, subject to HSR clearance and other customary conditions.
- Proceeds will be used to pay senior convertible notes due July 2023 and fund healthcare pipeline.
- Divestiture completes strategy to focus exclusively on healthcare, shedding the animal reproductive technologies unit.
- Rabo Securities acted as financial advisor; Davis Polk provided legal support.

## SEC filing metadata
- accession: 0000950103-22-011927
- form_type: 8-K
- ticker: PGEN
- cik: 0001356090
- company_name: PRECIGEN, INC.
- filed_at: 2022-07-05T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1356090/000095010322011927/0000950103-22-011927-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1356090/000095010322011927/dp176668_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950103-22-011927
- JSON: https://secwatch.observer/filing/0000950103-22-011927.json
- Plain text: https://secwatch.observer/filing/0000950103-22-011927.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.